Fig 2: SIGLEC15 mRNA expression correlation with DNA methylation and m6A regulator mRNA expression. (A–C) SIGLEC15 mRNA expression correlation with (A) m6A readers, (B) writers, and (C) erasers. (D) Each CpG methylation site level of SIGLEC15. (E) SIGLEC15 mRNA expression correlation with averaged CpG methylation site. (F–N) SIGLEC15 mRNA expression correlation with DNA methylation of each CpG methylation site.

Fig 3: Potential effective chemotherapy drugs with SIGLEC15. (A–K) Correlation of SIGLEC15 mRNA expression level and IC50 of different drugs based on the CellMiner database.

Fig 4: Differential mutational landscape in the high and low SIGLEC15 mRNA expression groups. (A) Genes were ranked according to the mutational frequency. SNV and Indel mutations in the high SIGLEC15 mRNA expression group. (B) Genes were ranked according to the mutational frequency. SNV and Indel mutations in the low SIGLEC15 mRNA expression group. (C, D) CNV landscape of (C) amplification and (D) deletion in the high and low SIGLEC15 mRNA expression groups; the chromosome was oriented vertically from top to bottom and GenePattern GISTIC2.0 q-value at each locus was placed from left to right. The green line displayed the cutoff value of q-value = 0.25.

Fig 5: Immunological cell patterns related to SIGLEC15. (A) Differences in the seven steps of the cancer immunity cycle between the high and low SIGLEC15 groups. (B) SIGLEC15 was associated with immune cell infiltration in THCA obtained from the TIMER database. (C) TME scores were compared between the high and low SIGLEC15 groups. (D) Scores were compared between the low and high SIGLEC15 groups in TIDE score and Exclusion score. (E) Enrichment scores for 16 immunocytes were compared between the low and high SIGLEC15 groups. (F) Enrichment scores for 13 immune-related pathways were compared between the low and high SIGLEC15 groups. ns, *, **, ***, and **** stand for p-value >0.05, p-value <=0.05, p-value <=0.01, pvalue <=0.001 and pvalue <=0.0001, respectively.